Health Technology
Eisai Co., Ltd.
In the news
- Governance demands chip away at Japanese cross-shareholdings Jul 8, 2019
- Eisai abandons Alzheimer's drug in late-stage testing Mar 22, 2019
- Itochu versus Descente -- investors stuck in the middle Mar 8, 2019
- 'Robot taxes' will help keep humans employed, Bill Gates predicts Nov 3, 2018
- Eisai teams with Merck to boost sales of cancer drug Mar 9, 2018 See more articles on Eisai Co., Ltd.
Business Summary
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 642,834M | 5,796.79M |
| Gross Profit | 446,436M | 4,025.76M |
| Operating income | 99,921M | 901.04M |
| Income before tax | 89,454M | 806.65M |
| Net income | 63,386M | 571.58M |
| EBITDA | 126,762M | 1,143.08M |
| Diluted EPS | 221.11 | 1.99 |
| Dividends Per Share | 150 | 1.35 |
| Total Assets | 1,071.52B | 9,680.80M |
| Total liabilities | 419,539M | 3,790.38M |
| Total equity | 628,120M | 5,674.84M |
| Operating cash flow | 103,714M | 935.24M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 548,465M | 547,922M | 539,097M | 600,054M | 642,834M |
| Gross Profit | 340,580M | 339,839M | 331,091M | 386,599M | 446,436M |
| Operating income | 27,778M | 42,779M | 51,205M | 75,595M | 99,921M |
| Income before tax | 25,875M | 50,473M | 57,668M | 76,803M | 89,454M |
| Net income | 43,254M | 54,933M | 39,359M | 51,845M | 63,386M |
| EBITDA | 66,718M | 76,843M | 77,689M | 101,778M | 126,762M |
| Diluted EPS | 151.37 | 191.76 | 137.41 | 180.97 | 221.11 |
| Dividends Per Share | 150 | 150 | 150 | 150 | 150 |
| Total Assets | 1,053.81B | 973,987M | 1,030.76B | 1,049.03B | 1,071.52B |
| Total liabilities | 451,757M | 397,159M | 428,172M | 434,934M | 419,539M |
| Total equity | 598,748M | 573,660M | 584,630M | 593,582M | 628,120M |
| Operating cash flow | 76,022M | 95,617M | 75,851M | 149,649M | 103,714M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 4,992.55M | 4,562.81M | 4,978.38M | 5,414.06M | 5,796.79M |
| Gross Profit | 3,100.22M | 2,830.00M | 3,057.51M | 3,488.14M | 4,025.76M |
| Operating income | 252.85M | 356.24M | 472.86M | 682.06M | 901.04M |
| Income before tax | 235.53M | 420.31M | 532.54M | 692.96M | 806.65M |
| Net income | 393.73M | 457.45M | 363.46M | 467.77M | 571.58M |
| EBITDA | 607.31M | 639.90M | 717.43M | 918.30M | 1,143.08M |
| Diluted EPS | 1.37 | 1.59 | 1.26 | 1.63 | 1.99 |
| Dividends Per Share | 1.36 | 1.24 | 1.38 | 1.35 | 1.35 |
| Total Assets | 8,787.30M | 8,665.75M | 9,250.32M | 9,863.94M | 9,680.80M |
| Total liabilities | 3,766.99M | 3,533.60M | 3,842.51M | 4,089.64M | 3,790.38M |
| Total equity | 4,992.68M | 5,103.96M | 5,246.61M | 5,581.39M | 5,674.84M |
| Operating cash flow | 692.01M | 796.24M | 700.45M | 1,350.22M | 935.24M |
Valuation Measures
| Mar 2019 | |
| PER | 28.06 |
| ROA | 5.97% |
| ROE | 10.37% |
| Operating margin | 15.54% |
| Profit margin | 9.86% |
Key executives
- Chief Executive Officer & Representative Director: Haruo Naito
- COO, Representative Executive Officer & Head-China: Yasushi Okada
- CFO & Chief Investor Relations Officer: Ryohei Yanagi
- Chief Medical Officer & Managing Executive Officer: Edward Stewart Geary
- Chief Medical & Chief Clinical Officer-Neurology: Lynn D. Kramer
Shareholders
- Wellington Management Co. LLP (8.6%)
- Nomura Asset Management Co., Ltd. (5.7%)
- Nippon Life Insurance Co. (4.1%)
- Asset Management One Co., Ltd. (3.4%)
- Eisai Co., Ltd. (3.3%)
- Nikko Asset Management Co., Ltd. (2.7%)
- Daiwa Asset Management Co. Ltd. (2.5%)
- The Vanguard Group, Inc. (2.4%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.4%)
- Resona Holdings, Inc. (2.3%)
Contact Details
- Website:http://www.eisai.co.jp
- Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
- Phone: +81.3.3817.3700
Related Companies
- Eisai Europe Ltd.
- Eisai LLC
- Eisai Machinery China Co. Ltd.
- Eisai Laboratorios S de RL de CV
- Eisai GesmbH
- Eisai Farmaceutica, Unipessoal Lda.
- Eisai Clinical Research Singapore Pte Ltd.
- Eisai Ltd. (Canada)
- Eisai SA/NV
- Eisai (Malaysia) Sdn. Bhd.
- Eisai (Thailand) Marketing Co. Ltd.
- Eisai AB
- Eisai Pharma AG
- Eisai (Singapore) Pte Ltd.
- Eisai Co. Ltd. /Misato Factory/
- Eisai Board Incentive Plan
- Eisai Corporate Pension Fund
- Eisai Pension Fund
- Eisai China, Inc.
- H3 Biomedicine, Inc.
- Eisai R&D Management Co., Ltd.
- Herusu Co., Ltd.
- Gakuen Shoji Co., Ltd.
- PT Eisai Indonesia
- Eisai Taiwan, Inc.
- Eisai (Hong Kong) Co. Ltd.
- Eisai Australia Pty Ltd.
- Eisai Pharmaceuticals India Pvt Ltd.
- Eisai GmbH
- Eisai SRL
Competitors
- JW Holdings Corporation
- MorphoSys AG
- Celltrion Pharm Inc.
- Nektar Therapeutics
- Ipsen SA
- Denali Therapeutics Inc.
- Blueprint Medicines Corp.
- Exelixis, Inc.
- TCR2 Therapeutics, Inc.
- Mirati Therapeutics Inc.
- Seattle Genetics, Inc.
- SillaJen, Inc.
- Aslan Pharmaceuticals Ltd.
- Xenon Pharmaceuticals Inc.
- AC Immune SA
- Genfit SA
- Infinity Pharmaceuticals, Inc.
- Aeolus Pharmaceuticals, Inc.
- Genkyotex SA
- Aquestive Therapeutics, Inc.
- Cortexyme, Inc.
- Vivoryon Therapeutics AG
- AVEO Pharmaceuticals, Inc.
- Heron Therapeutics Inc
- Phathom Pharmaceuticals, Inc.
- Cassava Sciences, Inc.
- Cytokinetics, Incorporated
- Onconova Therapeutics Inc.
- ProMIS Neurosciences Inc.
- Radius Health Inc
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Jan, 2020